Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Novartis AG (NOVN) Gets a Hold from UBS

Tipranks - Tipranks - Sat Apr 11, 2:01AM CDT

UBS analyst Matthew Weston maintained a Hold rating on Novartis AG today and set a price target of CHF116.00.

Easter Sale - 70% Off TipRanks

Weston covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, AstraZeneca, and Roche Holding AG. According to TipRanks, Weston has an average return of 10.2% and a 69.00% success rate on recommended stocks.

In addition to UBS, Novartis AG also received a Hold from Barclays’s James Gordon CFA in a report issued on March 27. However, on April 2, Kepler Capital maintained a Buy rating on Novartis AG (Six Swiss: NOVN).

See today’s best-performing stocks on TipRanks >>

Based on Novartis AG’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of CHF13.44 billion and a net profit of CHF2.43 billion. In comparison, last year the company earned a revenue of CHF13.56 billion and had a net profit of CHF2.82 billion

Read More on CH:NOVN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).